Rolston K V, Alvarez M E, Hoy J F, Alderman H C, Ho D H, Bodey G P
J Antimicrob Chemother. 1986 Aug;18(2):159-62. doi: 10.1093/jac/18.2.159.
The in-vitro activity of Sch 34343, a new penam antibiotic, was tested against 257 Gram-positive isolates from cancer patients, and compared with that of imipenem and amifloxacin. Sch 34343 was extremely active against beta-haemolytic streptococci (Lancefield groups A, B and G) with MIC90s ranging from 0.025 to 0.05 mg/l. It was also active against methicillin-susceptible Staphylococcus aureus and had variable activity against coagulase-negative staphylococci. MIC90 for Listeria monocytogenes was 0.78 mg/l and 84% of enterococcal isolates were inhibited by 6.25 mg/l.
对一种新型青霉烯类抗生素Sch 34343进行了体外活性测试，以检测其对257株来自癌症患者的革兰氏阳性菌的抗菌活性，并与亚胺培南和阿米氟沙星进行比较。Sch 34343对β-溶血性链球菌（兰斯菲尔德A、B和G组）具有极强的活性，其MIC90范围为0.025至0.05mg/l。它对甲氧西林敏感金黄色葡萄球菌也有活性，对凝固酶阴性葡萄球菌的活性则有所不同。单核细胞增生李斯特菌的MIC90为0.78mg/l，6.25mg/l的浓度可抑制84%的肠球菌分离株。
